The estimated Net Worth of Henry S Bienen is at least $22.7 Tausend dollars as of 29 May 2018. Henry Bienen owns over 10,000 units of Onconova Therapeutics Inc stock worth over $22,724 and over the last 11 years he sold ONTX stock worth over $0. In addition, he makes $0 as Director at Onconova Therapeutics Inc.
Sign up
Henry Bienen ONTX stock SEC Form 4 insiders trading
Henry has made over 4 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ONTX stock worth $3,800 on 29 May 2018.
The largest trade he's ever made was buying 10,000 units of Onconova Therapeutics Inc stock on 29 May 2018 worth over $3,800. On average, Henry trades about 1,094 units every 88 days since 2013. As of 29 May 2018 he still owns at least 22,724 units of Onconova Therapeutics Inc stock.
You can see the complete history of Henry Bienen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Henry Bienen biography
Dr. Henry S. Bienen, Ph.D., serves as Director of Onconova Therapeutics, Inc., since May 2009. He currently serves as the chairman of Rasmussen College, has served as the president emeritus of Northwestern University since 2009 and served as the president of Northwestern University from 1995 to 2009. Dr. Bienen was the James S. McDonnell Distinguished University Professor and Dean of the Woodrow Wilson School of Public and International Affairs at Princeton University prior to his appointment at Northwestern. Dr. Bienen began his association with Princeton University in 1966, advancing from assistant professor to professor of politics and international affairs, and was then appointed the William Stewart Tod Professor of Politics and International Affairs in 1981 and the James S. McDonnell Distinguished University Professor in 1985. Dr. Bienen has served as a director of Gleacher & Company, a publicly held investment banking firm, since May 2010, and the Grosvenor Registered Multi Strategy Fund (TI 1), LLC, the Grosvenor Registered Multi Strategy Fund (TI 2), LLC, the Grosvenor Registered Multi Strategy Fund (TE), LLC and the Grosvenor Registered Multi Strategy Master Fund, LLC since April 2011. Dr. Bienen previously served on the boards of directors of The Bear Stearns Companies Inc. until its purchase by JP Morgan Chase & Co. in 2008, and SPSS Inc. from 2007 until 2009, when the company was sold to IBM Corporation. Dr. Bienen received his Bachelor's Degree with honors from Cornell University and both his Master's Degree and Ph.D., from the University of Chicago.
How old is Henry Bienen?
Henry Bienen is 77, he's been the Director of Onconova Therapeutics Inc since 2009. There are no older and 12 younger executives at Onconova Therapeutics Inc.
What's Henry Bienen's mailing address?
Henry's mailing address filed with the SEC is 155 NORTH WACKER DRIVE, SUITE 4000, , CHICAGO, IL, 60606.
Insiders trading at Onconova Therapeutics Inc
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 und Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
What does Onconova Therapeutics Inc do?
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
What does Onconova Therapeutics Inc's logo look like?
Complete history of Henry Bienen stock trades at Onconova Therapeutics Inc und Ryan Specialty
Onconova Therapeutics Inc executives and stock owners
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Steven M. Fruchtman,
CEO, Pres & Director -
Manoj Maniar,
Senior Vice President - Product Development -
Mark Patrick Guerin CPA,
Chief Financial Officer -
Terri Shoemaker,
Director -
James Marino,
Chairman of the Board -
Anne VanLent,
Director -
Jack Stover,
Director -
Viren Mehta,
Director -
Jerome Groopman,
Director -
Henry Bienen,
Director -
Abraham Oler,
Vice President, Corporate Development and General Counsel -
Mark Guerin,
Chief Financial Officer -
Steven Fruchtman,
President, Chief Executive Officer, Director -
Dr. Ramesh Kumar Ph.D.,
Advisor -
Dr. Mark Stephen Gelder,
Chief Medical Officer -
Abraham N. Oler J.D., M.B.A., Esq., CFA,
Sr. VP of Corp. Devel. & Gen. Counsel -
Capital Management, Llc683 ...,
-
Capital Management, Llc683 ...,
-
Ramesh Kumar,
President and CEO -
Michael B Hoffman,
Director -
E Premkumar Reddy,
Director -
Capital Partners L P Tyndall,
10% owner -
Richard Charles Woodman,
Chief Medical Officer -
Capital Management, Llc 683,
10% owner -
Healthcare Sa Baxter,
10% owner -
Ajay Bansal,
Chief Financial Officer -
Thomas J Mckearn,
President, R&D -
& Jane Hoffman 2013 Descend...,
10% owner -
James Altland,
SVP, Finance & Corp. Develop. -
Healthcare Sabaxter Interna...,
-
Capital, Llc Armistice Capi...,
-
Mary Teresa Shoemaker,
-
Victor M Moyo,
CHIEF MEDICAL OFFICER -
Mark S. Md Gelder,
CHIEF MEDICAL OFFICER -
Peter Atadja,
-
Trafford Clarke,